Life Science Investing Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy in Sanfilippo Syndrome Type B
Life Science Investing Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Life Science Investing Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B
Forte Minerals Closes a Second C$5.7 Million Strategic Investment and Additional Participation from Existing Strategic Investor
LaFleur Minerals Provides Update on Confirmation Drilling for PEA at Swanson Gold Deposit and Beacon Gold Mill, Val-d'Or, Québec
Cartier Cuts 111.5 g/t Au over 2.0 m at Contact ; Confirms Multiple High-Grade Gold Zones; Extends Drilling at Surface
